检索结果-南通市图书馆

中国医疗器械杂志 1995年第4期19卷 203-207,212页

作者：陈新林立平中村彰内野淳福州大学福建省立医院日本长崎大学

本文讨论脑萎缩率定量测量中各区域的识别方法，并简要介绍脑萎缩率定量测量系统。

关键词：脑萎缩率定量测量 CT

记忆临床病人全脑萎缩率和认知功能损害的纵向MR研究

在线全文

学校读者我要写书评

暂无评论

国际医学放射学杂志 2008年第5期31卷 406-406页

作者： J.D. Sluimer W.M. van der Flier G.B. Karas N.C. Fox P. Scheltens F.Barkhof 郭雪梅（译）唐光健（校） Alzheimer Centre and Department of Diagnostic Radiology Image Analysis Centre Vrije Universiteit Medical Centre （VUMC） De Boelelaan 1117 1007 MB Amsterdam the Netherlands. 不详

目的前瞻胜地研究轻度认知功能障碍（MCI）和阿尔茨海默病（AD）的全脑萎缩率及其与认知功能损害的关系，研究已有基础脑容量与全脑萎缩率，但尚未痴呆的病人发展为痴呆的概率。方法本研究经学术审查委员会批准并取得所有病人书面的知... 详细信息

目的前瞻胜地研究轻度认知功能障碍（MCI）和阿尔茨海默病（AD）的全脑萎缩率及其与认知功能损害的关系，研究已有基础脑容量与全脑萎缩率，但尚未痴呆的病人发展为痴呆的概率。方法本研究经学术审查委员会批准并取得所有病人书面的知情同意。65例AD病人（女38例，男27例；年龄52～81岁），45例MCI病人（女22例，男23例；年龄56～80岁），27例有主观症状的病人（女12例。男15例；年龄50～87岁），以及10名健康人（女6例，男4例；年龄53-80岁）作为对照纳入研究。2次MR检查时间间隔为（1．8±0．7）a。采用3DT1WI（1．0T，单块采集，168层，

关键词：认知功能损害脑萎缩率 MR检查临床病人轻度认知功能障碍记忆阿尔茨海默病主观症状

多发性硬化症的治疗时机窗:单克隆抗体治疗的依据

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（神经病学分册） 2006年第5期2卷 39-40页

作者： Coles A.J Cox A Le Page 张慧 Department of Clinical Neurosciences Box 165 Addenbrooke's Hospital Cambridge CB2 2QQ United Kingdom

From 1991- 2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath-1H, which causes prolonged T lymphocyte depletion. Clinical and surrogate markers of inflammation were suppressed. In both the relapsing-remitting (RR) and secondary progressive (SP) stages of the illness, Campath-1H reduced the annual relapse rate (from 2.2 to 0.19 and from 0.7 to 0.001 respectively; both p < 0.001). Remarkably, MRI scans of patients with SP disease, treated with Campath-1H 7 years previously, showed no new lesion formation. However, despite these effects on inflammation, disability was differently affected depending on the phase of the disease. Patients with SPMS showed sustained accumulation of disability due to uncontrolled progression marked by unrelenting cerebral atrophy, attributable to ongoing axonal loss. The rate of cerebral atrophy was greatest in patients with established cerebral atrophy and highest inflammatory lesion burden before treatment (2.3 versus 0.7 ml/year; p = 0.04). In contrast, patients with RR disease showed an impressive reduction in disability at 6 months after Campath-1H (by a mean of 1.2 EDSS points) perhaps owing to a suppression of on-going inflammation in these patients with unusually active disease. In addition, there was a further significant, albeit smaller, mean improvement in disability up to 36 months after treatment. We speculate that this represents the beneficial effects of early rescue of neurons and axons from a toxic inflammatory environment, and that prevention of demyelination will prevent long-term axonal degeneration. These concepts are currently being tested in a controlled trial comparing Campath-1H and IFN-beta in the treatment of drug-na ve patients with early, active RR MS.

关键词：多发性硬化症人单克隆抗体抗体治疗治疗时机依据脑萎缩率 RRMS 轴突变性年复发率早期恢复

进行性核上性麻痹和多系统萎缩的纵向MRI检查:萎缩率和部位

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（神经病学分册） 2006年第9期2卷 40-41页

作者： Paviour D. C. Price S. L Jahanshahi M. 张慧(译) Sara Koe PSP Research Centre Institute of Neurology UCL London United Kingdom 不详

The rate of brain atrophy and its relationship to clinical disease progression in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) is not clear. Twenty-four patients with PSP, 11 with MSA-P (Parkinsonian variant), 12 with Parkinson’s disease, and 18 healthy control subjects were recruited for serial MRI scans, clinical assessments and formal neuropsychological evaluations in order to measure brain atrophy during life and its association with disease progression in PSP and MSA-P. Serial scans were registered and rates of whole brain atrophy calculated from the brain-boundary shift integral. Regional rates of atrophy were calculated in the brainstem (midbrain and pons), the cerebellum, the lateral and third ventricles as well as frontal and posterior inferior brain regions, by locally registering to a region of interest in order to derive a local boundary shift integral (BSI). 82%of recruited subjects completed serial MRI scans (17 PSP, 9 MSA-P, 9 Parkinson’s disease patients and 18 healthy controls). Mean (SD) annualized rates of whole-brain atrophy were greatest in PSP: 1.2%(1.0%), three times that in controls. Mean (SD) midbrain atrophy rates in PSP, 2.2%(1.5%), were seven times greater than in healthy controls. In MSA-P, atrophy rates were greatest in the pons: 4.5%(3.2%), over 20 times that in controls and three times the rate of pontine atrophy in PSP. Atrophy rates in Parkinson’s disease were not significantly different from control rates of atrophy. Variability in the atrophy rates was lower when calculated using the BSI rather than manual measurements. Worsening motor deficit was associated with midbrain atrophy in PSP, and pontocerebellar atrophy in MSA-P. Worsening executive dysfunction was associated with increased rates of frontal atrophy in PSP. Cerebellar atrophy rates were better discriminators of MSA-P than cross-sectional *** confirm that serial MRI can be applied to measure whole brain and regional atrophy rates in PSP a

关键词：进行性核上性麻痹 MRI检查多系统萎缩脑桥小脑萎缩脑萎缩率心理学评估执行功能障碍疾病进展